Skip to main content
RCKT
NASDAQ Life Sciences

Stockholders Approve Option Exchange Program and Director Elections

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3
Mkt Cap
$324.305M
52W Low
$2.19
52W High
$6.885
52W Position info
37% above low
Off High info
56% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

RCKT sits 37% above its 52-week low of $2.19.

Summary

Rocket Pharmaceuticals' stockholders approved a stock option exchange program and the election of directors at its annual meeting.


Key Events · Corporate Governance and Compliance · RCKT

  • Stock Option Exchange Program Approved

    Stockholders approved a program to exchange existing stock options, with 17.6 million votes against the proposal, indicating notable shareholder dissent.

  • Director Elections

    Seven directors were re-elected to the Board, including David P. Southwell, who received a significant number of 'Votes Withheld' (20.1 million).

  • Executive Compensation Approved

    The non-binding advisory vote on the compensation of named executive officers passed.

  • Auditor Ratification

    EisnerAmper LLP was ratified as the independent registered accounting firm for the fiscal year ending December 31, 2026.


Analysis · RCKT · Life Sciences

The approval of the stock option exchange program is a key corporate governance decision. While intended to re-incentivize employees, it carries the potential for future dilution, as evidenced by the significant number of votes against the proposal. This comes after recent positive news like FDA approval and a Priority Review Voucher sale, suggesting the company is trying to stabilize its talent base during a turnaround.

How filings like this one have moved

In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RCKT was trading at $3.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $324.3M. The 52-week trading range was $2.19 to $6.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RCKT - Latest Insights

RCKT
Sep 15, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.49
Real-time Price: $2.61 info
Change: -$0.880 (-25%) info
Market Cap: $281.023M info
RCKT
Sep 15, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $3.45
Real-time Price: $2.61 info
Change: -$0.840 (-24%) info
Market Cap: $281.023M info
RCKT
Aug 10, 2026, 4:00 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $3.63
Real-time Price: $2.61 info
Change: -$1.02 (-28%) info
Market Cap: $281.023M info
RCKT
Aug 03, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.14
Real-time Price: $2.61 info
Change: -$0.530 (-17%) info
Market Cap: $281.023M info
RCKT
Aug 03, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $3.14
Real-time Price: $2.61 info
Change: -$0.530 (-17%) info
Market Cap: $281.023M info